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Introduction {#sec005}
============

Very elderly critically ill patients (ie, those older than 75 or 80 years) are an increasing population in intensive care units (ICU) \[[@pone.0238124.ref001], [@pone.0238124.ref002]\]. However, there is much controversy on how these patients should be managed. Although selected patients seem to benefit from ICU admission, elderly patients tend to have more ICU rejections \[[@pone.0238124.ref003]\] and a policy of systematic ICU admission of these patients has no positive effect on both short and long-term outcomes \[[@pone.0238124.ref004]\].

Recent research has focused on the epidemiology of elderly patients to identify the clinical path they follow after the ICU admission. As expected, those studies have showed increased mortality rates when compared to younger patients. However, mortality rates in the range of 20--40% may be considered acceptable under such patients' conditions \[[@pone.0238124.ref005]--[@pone.0238124.ref009]\]. Nevertheless, the vast majority of studies in this population were performed in high-income countries \[[@pone.0238124.ref005]--[@pone.0238124.ref009]\], which raises concerns on the generalization of results to low-and, more particularly, middle-income countries where half of the world population live and demographic changes have been accelerated \[[@pone.0238124.ref010]\].

In parallel, a considerable improvement in outcomes of critically ill cancer patients was observed in recent years \[[@pone.0238124.ref011]\]. Despite these findings, cancer is still considered a condition predisposing denial of ICU admission in elderly critically ill patients \[[@pone.0238124.ref004]\]. However, as anticancer therapies become safer and more effective, a larger number of elderly individuals are being treated \[[@pone.0238124.ref012], [@pone.0238124.ref013]\]. Moreover, the increased indications of surgical and pharmacologic interventions have expanded the need for intensive care for monitoring after procedures or treatment-related complications. Although there is no evidence to manage elderly critically ill patients with cancer differently from patients without cancer, evidence supporting this premise is very scarce \[[@pone.0238124.ref014]\]. To bridge this gap, we performed a multicenter study in Brazil to describe clinical characteristics, outcomes and to identify factors associated with hospital mortality of a large cohort of patients aged 80 years or older with cancer admitted to ICUs.

Methods {#sec006}
=======

Design and setting {#sec007}
------------------

This was a retrospective study on prospectively collected data from two databases. The first is from the Orchestra study \[[@pone.0238124.ref015]\], a multicenter study performed in 93 ICUs from 55 hospitals in several Brazilian states from January 2014 to December 2015, and the second, from the A.C. Camargo Cancer Center, a dedicated cancer center in São Paulo Brazil, with 50 ICU beds, from January 2011 to December 2017. A.C. Camargo Cancer Center Local Ethics Committees (CAAE: 86761718.0.0000.5432) and the Brazilian National Ethics Committee (CAAE: 19687113.8.1001.5249) approved the study without the need for informed consent, since all data were fully anonymized before researches could access them.

Patients {#sec008}
--------

We included all patients aged 80 years or older with active cancer who were admitted to the participant ICUs during the study period. We excluded patients admitted after elective surgeries.

Data collection {#sec009}
---------------

We retrieved patients' data from the Epimed Monitor System (Epimed Solutions, Rio de Janeiro, Brazil) \[[@pone.0238124.ref016]\] as in other analysis of the Orchestra study and from the local database from A.C. Camargo Cancer Center. Trained healthcare workers inserted all clinical data in both databases. All data were deidentified. We collected data on patients' sex and age, type of ICU admission (medical, elective or urgent surgical), cancer type (hematological, solid locoregional or metastatic), performance status before hospital admission (evaluated by Eastern Cooperative Oncology Group \[ECOG\] categorized as absent/minor impairment, ie, ECOG 0 or 1, or moderate/severe impairment, categorized as ECOG 2 to 4) \[[@pone.0238124.ref017]\], a modified Charlson Comorbidity Index (CCI), which did not take into account points related to cancer status, the Simplified Acute Physiology Score (SAPS 3), use of organ support during ICU stay (vasopressors, invasive mechanical ventilation and renal replacement therapy), ICU and hospital length of stay (LOS), ICU and hospital mortality.

The primary outcome was hospital mortality. There was no missing data on the outcome. Information on performance status was absent for 193 patients (4.2%). There was minimal (\<1%) missing data on mechanical ventilation, vasopressors and renal replacement use. There was no missing data on type of cancer, type of admission and CCI. We did not perform any imputation on these missing data and performed complete-case analysis.

Statistical analysis {#sec010}
--------------------

This study was mainly descriptive of the population of interest. We did not perform neither sample size nor power calculations, instead we present all available data from the included patients. All data are presented as frequencies (percentages) for categorical variables and as means (standard deviations) for continuous variables. We used chi-square test of independence for categorical variables and independent samples t-test test for continuous variables to compare two groups. Our variable of interest was hospital mortality.

We performed a mixed effect logistic regression model, with ICU as a random-effect, with predefined covariates (type of admission, type of cancer, performance status, modified CCI and use of mechanical ventilation, vasopressors and renal replacement therapy during ICU LOS) to evaluate its association with hospital mortality. We evaluated collinearity among the variables included in the models by calculating the Variation Inflation Factor (VIF). Arbitrarily, we considered VIF ≥ 2 as a diagnostic of multicollinearity. Odds ratio (OR) and 95% confidence intervals (CI 95%) were calculated for all these variables. In order to validate the prediction of the model, we randomly split the data into train (70%) and validation samples (30%). Calibration was evaluated by plotting the actual observed event frequency against the average predicted probability for each decile of a population, and qualitatively assessing the deviation from a diagonal line. Model discrimination power was assessed with area under the receiver operator curve (AUC). We used R version 3.5.1 for all analysis with the following packages lme4, dplyr and ggplot2.

Results {#sec011}
=======

There were 4604 eligible patients in the two databases during the study periods ([Fig 1](#pone.0238124.g001){ref-type="fig"}). Out of them, 856 (18.6%) patients were 90 years or older; 22 (0.5%) were 100 years or older. A total of 980 (21.3%) of patients died in ICU and 1807 (39.2%) died in hospital. Patients who did not survive to hospital stay had more metastatic and hematologic tumors, were more commonly admitted for medical reasons, had worse performance status and a higher burden of comorbidities. On the other hand, age was not associated with higher hospital mortality. Deceased patients used more invasive mechanical ventilation, vasopressor and renal replacement therapies during ICU LOS. Patients who deceased also have longer ICU and hospital length-of-stays ([Table 1](#pone.0238124.t001){ref-type="table"}).

![Study flowchart.](pone.0238124.g001){#pone.0238124.g001}

10.1371/journal.pone.0238124.t001

###### Patients' characteristics.

![](pone.0238124.t001){#pone.0238124.t001g}

  Variables                                                       Alive (n = 2797)   Deceased (n = 1807)   p
  --------------------------------------------------------------- ------------------ --------------------- --------
  Female sex, N (%)                                               1349 (48.2)        883 (48.9)            0.67
  Age, years; mean (SD)                                           85.6 (4.3)         85.7 (4.3)            0.29
  Type of cancer, N (%)                                                                                    \<0.01
      *Solid*, *locoregional*                                     2027 (72.5)        1001 (55.4)           
      *Solid*, *metastatic*                                       556 (19.9)         602 (33.3)            
      *Hematological*                                             214 (7.7)          204 (11.3)            
  Type of admission, N (%)                                                                                 \<0.01
      *Emergency surgery*                                         281 (10.0)         134 (7.4)             
      *Medical*                                                   2516 (90.0)        1673 (92.6)           
  Modified CCI, points; mean (SD)                                 1.9 (1.1)          2.0 (1.2)             0.02
  Performance status, N(%)[\*](#t001fn002){ref-type="table-fn"}                                            \<0.01
      *ECOG 0--1*                                                 1172 (41.9)        597 (33.0)            
      *ECOG 2--4*                                                 1506 (53.8)        1136 (62.9)           
  Reason for admission, N (%)                                                                              \<0.01
      *Sepsis*                                                    928 (33.2)         711 (39.3)            
      *Cardiovascular*                                            421 (15.1)         147 (8.1)             
      *Respiratory*                                               245 (8.8)          267 (14.8)            
      *Neurological*                                              322 (11.5)         167 (9.2)             
      *Renal/Metabolic*                                           141 (5.0)          95 (5.3)              
      *Gastrointestinal*                                          246 (8.8)          111 (6.1)             
  SAPS 3, points; mean (SD)                                       60.0 (11.8)        70.0 (16.2)           \<0.01
  ICU Complications, N (%)                                                                                 
  *Vasopressor*                                                   351 (12.5)         695 (38.5)            \<0.01
  *Mechanical ventilation*                                        261 (9.3)          793 (43.9)            \<0.01
  *Renal replacement therapy*                                     110 (3.9)          207 (11.5)            \<0.01
  ICU LOS, days; mean (SD)                                        4.6 (5.7)          8.0 (11.3)            \<0.01
  Hospital LOS, days; mean (SD)                                   19.1 (28.2)        26.4 (57.2)           \<0.01

CCI: Charlson Comorbidity Index. ECOG: Eastern Cooperative Oncology Group. ICU: Intensive Care Unit. LOS: Length of Stay. SAPS: Simplified Acute Physiology Score. SD: Standard Deviation.

\*Data on ECOG was absent for 193 (4.2%) patients.

Most patients had solid tumors (n = 4186, 90.9%). Prostate, colorectal, breast and lung were the most common site of solid tumors. Lung cancer was more common among patients who deceased, while prostate cancer was more common among patients who survived to hospital discharge. Among patients with hematological tumors (n = 418, 9.1%), lymphomas, leukemias and multiple myeloma were the most common type of tumors and occurred at similar patterns among patients who did and did not survive to hospital discharge ([Table 2](#pone.0238124.t002){ref-type="table"}).

10.1371/journal.pone.0238124.t002

###### Type of tumors.

![](pone.0238124.t002){#pone.0238124.t002g}

  Solid tumors, N (%)         Alive (n = 2583)   Deceased (n = 1603)
  --------------------------- ------------------ ---------------------
  Prostate                    559 (21.6)         266 (16.6)
  Colorectal                  342 (13.2)         224 (14.0)
  Breast                      386 (14.9)         184 (11.5)
  Lung                        213 (8.2)          186 (11.6)
  Head and neck               181 (7.0)          97 (6.0)
  Renal                       164 (6.3)          99 (6.2)
  Stomach                     87 (3.3)           66 (4.1)
  Pancreas                    87 (3.3)           74 (4.6)
  Central nervous system      81 (3.1)           53 (3.3)
  Liver and biliary tree      71 (2.7)           70 (4.4)
  Hematological tumors, N (   Alive (n = 214)    Deceased (n = 204)
  Lymphoma                    87 (40.6)          87 (42.6)
  Leukemia                    58 (27.1)          53 (26.0)
  Multiple myeloma            63 (29.4)          50 (24.5)

There was no multicollinearity among the predefined variables to be included in the logistic regression model ([Table 3](#pone.0238124.t003){ref-type="table"}).

10.1371/journal.pone.0238124.t003

###### Variation inflation index of the selected variables to be included in the logistic regression model.

![](pone.0238124.t003){#pone.0238124.t003g}

  Variable                    VIF
  --------------------------- -------
  Type of admission           1.018
  Type of cancer              1.096
  Performance status          1.008
  Mechanical ventilation      1.374
  Vasopressors                1.387
  Renal replacement therapy   1.097
  Modified CCI                1.112

CCI: Charlson Comorbidity Index. VIF: Variation Inflation Index.

Metastatic cancer and hematologic cancer were independently associated with hospital mortality in comparison with locoregional solid tumors. Emergency surgical admissions were associated with lower hospital mortality than medical admissions. Performance status impairment, need for mechanical ventilation, vasopressors and renal replacement therapy were all also associated with increased hospital mortality ([Fig 2](#pone.0238124.g002){ref-type="fig"}). The model had a good discrimination ([S1 Fig](#pone.0238124.s001){ref-type="supplementary-material"}) power and was well calibrated ([S2 Fig](#pone.0238124.s002){ref-type="supplementary-material"}).

![Mixed effect logistic regression analysis for risk factors associated with hospital mortality.](pone.0238124.g002){#pone.0238124.g002}

Discussion {#sec012}
==========

Our study showed that main clinical short-term outcomes for elderly critically ill cancer patients requiring ICU admission are reasonable. The observed mortality rates were comparable to those reported in the literature for younger patients with cancer \[[@pone.0238124.ref011], [@pone.0238124.ref018]\] or undifferentiated elderly critically ill patients \[[@pone.0238124.ref009], [@pone.0238124.ref019]\]. In the present study, type of cancer, type of ICU admission, performance status and acute organ dysfunctions were all associated with increased hospital mortality.

Patients with cancer have been only a minority in large epidemiological studies of very old critically ill patients \[[@pone.0238124.ref005], [@pone.0238124.ref008]\]. Our study suggests elderly critically ill patients with cancer had a similar hospital mortality to those without cancer reported in previous studies \[[@pone.0238124.ref005], [@pone.0238124.ref007]\]. Use of vasopressors and renal replacement therapy in the patients of our study were similar to those of the studies of undifferentiated elderly critically ill patients \[[@pone.0238124.ref005]--[@pone.0238124.ref007]\], reinforcing similar severity among them.

Among baseline characteristics, performance status and type of cancer were associated with increased mortality. Performance status has widely been known as a prognostic factor in critically ill patients \[[@pone.0238124.ref017]\] and also, specifically, in elderly \[[@pone.0238124.ref020]\] and patients with cancer admitted to ICU \[[@pone.0238124.ref021]\]. As expected, the proportion of patients with at least moderate impairment of performance status in our study (60%) was much higher than that reported in studies of general critically ill patients \[[@pone.0238124.ref017]\]. However, the rates of performance status impairment found in our study are even higher than that found in some cohorts of elderly critically ill patients \[[@pone.0238124.ref022]\], suggesting that cancer burden may impact negatively on performance status of very old patients.

One specific finding of our study was that metastatic solid cancer and hematologic cancer were also associated with increased hospital mortality. Previous studies in critically ill patients with cancer have not consistently shown that type of cancer had such an impact \[[@pone.0238124.ref021]\]. It seems cancer status has a role only in mortality beyond 120 days \[[@pone.0238124.ref023], [@pone.0238124.ref024]\]. Our study suggests that, in a different manner from their younger counterparts, type of cancer has an impact on short-term outcomes of elderly critically ill patients. Therefore, performance status and type of cancer are two known characteristics at ICU admission which may be taken into account on decisions for care and on prognostic information of elderly critically ill patients with cancer.

Understanding the epidemiology and outcomes of elderly critically ill patients in middle-income countries is of paramount importance because these countries have been facing with a more accelerated demographic change than that faced by high-income countries in the end of 20^th^ century \[[@pone.0238124.ref010]\]. Additionally, since rational resource utilization has been another challenge faced by middle-income countries, collaboration among intensivists, oncologists \[[@pone.0238124.ref025]\] and geriatricians \[[@pone.0238124.ref026]\] to the care of these patients will be fundamental.

Our study has some limitations. First, we could not assess frailty in our study patients. Frailty has been shown to be an important marker of mortality in critically ill, elderly and cancer patients \[[@pone.0238124.ref027]\]. Second, we also did not assess withholding or withdrawal of life-sustaining therapies. These decisions are obviously associated with increased mortality rates and may have had an impact on study patients' outcomes \[[@pone.0238124.ref028]\]. Third, we only have data on patients who were admitted to ICU. We cannot point out whether patients' which ICU admission was refused were more or less severely ill than those admitted neither they have or not worse outcomes. Finally, data on long-term survival and patient reported outcomes other than short-term mortality were unavailable.

Our study has also some strengths. It is a large multicenter cohort in middle-income country. Therefore, it adds information to those of high-income studies on elderly critically ill patients. Additionally, it sheds light on a population poorly described in the previous studies: elderly critically ill patients with cancer. Although these patients tend to have their ICU admission refused, it seems they also benefit from ICU admission in terms of short-term mortality. Whether this benefit is sustainable to long-term outcomes is current unknown.

In conclusion, elderly critically ill patients with cancer have comparable short-term outcomes after ICU admission to those of elderly patients without cancer reported in literature. Traditional markers of severity, such as medical admissions, use of life-sustaining therapies and performance status are also associated with increased mortality in elderly patients with cancer. In a different manner from their younger counterparts, metastatic solid cancer and hematologic cancer are associated with increased mortality in elderly critically ill patients and should be taken into consideration when planning care of these patients.
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Reviewer \#1: This is indeed an interesting question in the cancer setting. However, I have two major issues with the statistical analyses performed, and hence the discussion and conclusion.

Dear reviewer,

Thank you for your time spent on peer-review.

1\) If the outcome is mortality, why did you do logistic regression? Why did you not consider Cox regression and time to death?

We chose logistic regression because our aim was to evaluate factors associated with a specific event (i.e., hospital mortality). We did not intend to study a time to event outcome.

Additionally, a Cox regression model would not be appropriate for this study because some of the predefined variables (type of cancer, use of vasopressors and renal replacement therapy) included in the model did not respect the proportion hazards assumption according to the Schoenfeld residuals method, as can be seen in the figure in the attached file.

Therefore, in order to verify the association of the predefined covariates with the hospital mortality, we believe it would be more appropriate to perform a logistic regression model.

2\) The variables in the model may suffer from collinearity and hence it is recommended to create a directed acyclic graph to identify which variables should go into the model and how to estimate their independent effects on the outcome of interest.

We agree with the reviewer about collinearity. In the revised manuscript, We evaluated collinearity among the variables included in the models by calculating the Variation Inflation Factor (VIF). Arbitrarily, we considered, in a conservative approach, a VIF ≥ 2 as a diagnostic of multicollinearity. We added a sentence in Methods: "We evaluated collinearity among the variables included in the models by calculating the Variation Inflation Factor (VIF). Arbitrarily, we considered VIF ≥ 2 as a diagnostic of multicollinearity." We also added the results of multicollinearity assessment in Results:

"There was no multicollinearity among the predefined variables to be included in the logistic regression model (Table 3).

Table 3. Variation inflation index of the selected variables to be included in the logistic regression model

Variable VIF

Type of admission 1.018

Type of cancer 1.096

Performance status 1.008

Mechanical ventilation 1.374

Vasopressors 1.387

Renal replacement therapy 1.097

Modified CCI 1.112

CCI: Charlson Comorbidity Index. VIF: Variation Inflation Index."

Reviewer \#2: This is an interesting piece of work with a few areas which could benefit from additional clarification;

Dear reviewer,

Thank you for your time spent on peer-review.

How representative of the population as a whole is the population which is served by the two centres included in this study. Are the results scalable?

Actually, this study was carried out with data from 56 centers. One of the databases is from a multicenter study with 55 hospitals (Orchestra study) and the other from a single large cancer center (A.C. Camargo Cancer Center). We believe the results are representative of Brazilian hospitals dedicated to care of patients with cancer.

It is not entirely clear from the methods how confident the authors were with the completeness of variables such as cancer status which were used to identify the cohort.

We agree with the reviewer that this information was not entirely clear. In the revised manuscript, we included the sentences: "There was no missing data on the outcome. Information on performance status was absent for 193 patients (4.2%). There was minimal (\<1%) missing data on mechanical ventilation, vasopressors and renal replacement use. There was no missing data on type of cancer, type of admission and CCI. We did not perform any imputation on these missing data and performed complete-case analysis."

How was the reason for admission to ICU defined?

In Orchestra database, reason for admission is extracted from a form fulfilled by a nurse or physician from the included ICU. In A.C. Camargo database, reason for admission is extracted from medical charts. The reason for admission is fulfilled by the intensivist in charge of the patient at the time of admission. In both databases, diagnoses are further categorized as sepsis, trauma or a disorder in an organ/system (neurologic, cardiovascular, respiratory, renal, gastrointestinal, surgical and others).

There is no mention in the methods as to whether patients were on active treatment for their cancer at the time of admission to ICU, and if they were, what that was. This may be significantly impacting on the results of the study.

It was an inclusion criteria for the study that patients were on active treatment for their cancer (In Methods, Patients, we highlighted this status in the revised manuscript: "We included all patients aged 80 years or older with active cancer who were admitted to the participant ICUs during the study period. We excluded patients admitted after elective surgeries."). However, we don't have, in neither database which were the treatment patients were on (for example, chemotherapy, target therapies, radiotherapy, etc).

The message of the paper becomes a little confused in the discussion, the final paragraph of the paper is unclear. The focus appears to switch from being the impact of age on ICU mortality to being the impact of cancer on mortality in the very elderly. This could be made much stronger.

We agree with the reviewer and apologize for not being clear. We believe we have two main messages. We have tried to emphasize both in the revised manuscript:

1\. Short-term mortality of elderly critically ill patients with cancer was not worse than that from elderly critically ill patients without cancer. Thus, in the second paragraph of discussion, we have written: "Our study suggests elderly critically ill patients with cancer had a similar hospital mortality to those without cancer reported in previous studies \[5, 7\]. Additionally, in conclusion, we have written "elderly critically ill patients with cancer have comparable short-term outcomes after ICU admission to those of elderly patients without cancer reported in literature."

2\. Type of cancer is associated with short-term mortality in elderly critically ill patients with cancer, what has not been consistently shown in previous studies in critically ill patients with cancer. In the fourth paragraph of discussion, we have written: "One specific finding of our study was that metastatic solid cancer and hematologic cancer were also associated with increased hospital mortality. Previous studies in critically ill patients with cancer have not consistently shown that type of cancer had such an impact\[21\]. (...) Our study suggests that, in a different manner from their younger counterparts, type of cancer has an impact on short-term outcomes of elderly critically ill patients." Additionally, in conclusion, we have writen: "In a different manner from their younger counterparts, metastatic solid cancer and hematologic cancer are associated with increased mortality in elderly critically ill patients and should be taken into consideration when planning care of these patients."

Reviewer \#3: Very old patients with cancer admitted to intensive care unit: A multicentre study in a middle-income country.

The authors have performed a study aiming to describe clinical characteristics and identify factors associated with hospital mortality in a cohort of very old patients with cancer admitted to intensive care units.

Dear reviewer,

Thank you for your time spent on peer-review.

The analyses are well performed and the only thing that makes me hesitate to recommend this paper for publication is the lack of information about the selection of patients to the study.

On page 3 line 78 the authors mention that cancer "is still considered a condition predisposing denial of ICU admission...".

What kind of patients are in this study? They have cancer, but it's hard to tell from the information given in the paper what cancer patients that are denied ICU admission. What are the characteristics for patients in the ICU without cancer?

Thank you for the consideration. In the sentence mentioned previously, we had just tried to contextualize our study in the previous knowledge of critically ill patients. The study by Guidet et al (Guidet B, Leblanc G, Simon T, Woimant M, Quenot JP, Ganansia O, et al. Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France: A Randomized Clinical Trial. Jama. 2017;318(15):1450-9.), which we cite after this sentence, aimed to evaluate whether a liberal ICU admission policy in elderly critically ill patients could reduce long-term mortality. However, elderly patients with cancer were excluded from this trial, possibly because it may be common sense that elderly patients with active cancer wouldn't benefit from liberal ICU admission policies. Unfortunately, because of both databases are from patients ultimately admitted to ICU, we don't have data on critically ill patients which ICU admission was denied or simply not considered.

Some of the cancers presented in Table2 (at least prostate cancer detected with a PSA-test) can be associated with a better health status than the background population <https://zerocancer.org/learn/about-prostate-cancer/facts-statistics/>.

If a screening program for breast cancer is present in Brazil, the same argument can be applied for breast cancer.

Why did the authors compare these patients to patients of similar age but without cancer?

We agree with the reviewer. In Brazil, we have a screening program for breast cancer too and maybe patients identified in screening programs may be associated with better health status. Anyway, our main aim was to describe a population of elderly critically ill patients with any type of cancer. Although patients with different types of cancer may have different long-term outcomes, we believe most healthcare personnel who take care of critically ill patients still see cancer as a unique variable. Additionally, unfortunately, we don't have data on elderly patients without cancer from this study and can't make such comparison.
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Dear Dr. Nassar Junior,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Valérie Pittet, PhD
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